EZH2 and gastric cancer: As measured by qPCR, the expression of EZH2 was significantly increased in all tumors (×3, p < 0.0001), intestinal and diffuse GCs (Table 1 and Figure 1), along with significant overexpression (75% and 23%, respectively, p = 0.016) in GC subtypes (Supplementary Table S1A,B).